CS
ATRA icon

Candriam SCA’s Atara Biotherapeutics ATRA Stock Holding History

Candriam SCA’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,846
Closed -$390K – 731
2023
Q1 		$390K Sell
5,846
-1,796
-24% -$174K ﹤0.01% 827
2022
Q4 		$627K Sell
7,642
-1,342
-15% -$140K ﹤0.01% 779
2022
Q3 		$849K Buy
+8,984
New +$1.01M 0.01% 743
2016
Q2 		– Sell
-2,220
Closed -$1.05M – 659
2016
Q1 		$1.05M Buy
+2,220
New +$999K 0.03% 422
2015
Q4 		– Sell
-1,628
Closed -$1.28M – 580
2015
Q3 		$1.28M Buy
1,628
+1,028
+171% +$1.25M 0.03% 407
2015
Q2 		$791K Buy
+600
New +$688K 0.02% 477

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.6B AUM 48.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return